Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TERESITA SALAZAR-GUADIZ

Allopathic & Osteopathic Physicians Pediatrics

NPI
1548343932
CMS profile
297492
Location
BELLFLOWER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$44.94

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $44.94 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Cipher Pharmaceuticals US LLC $24.90 1
Merck Sharp & Dohme LLC $20.04 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TERESITA SALAZAR-GUADIZ

NPI 1548343932 · CMS profile ID 297492

Allopathic & Osteopathic Physicians / Pediatrics

BELLFLOWER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548343932?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TERESITA SALAZAR-GUADIZ, NPI 1548343932, CMS profile ID 297492. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548343932?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). TERESITA SALAZAR-GUADIZ, NPI 1548343932, CMS profile ID 297492. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548343932?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
TERESITA SALAZAR-GUADIZ, NPI 1548343932, CMS profile ID 297492, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1548343932?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $44.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $20.0405/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238100834 CMS
Cipher Pharmaceuticals US LLC $24.9001/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250594452 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,383.84 13
PY2020 $23.79 1
PY2021 $86.93 3
PY2022 $29.11 2
PY2023 $39.35 2
PY2024 $38.59 2
PY2025 $44.94 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $330,729.26 26
PY2024 Principal investigator $570,067.62 29
PY2023 Principal investigator $1,106,110.39 48
PY2022 Principal investigator $239,768.15 21
PY2021 Principal investigator $239,538.66 55
PY2020 Principal investigator $173,482.29 68
PY2019 Principal investigator $75,987.19 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,206.45 12/16/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742894391
Principal investigator 1 Merck Sharp & Dohme Corporation $4,605.48 12/01/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756499
Principal investigator 1 PFIZER INC. $2,045.85 11/21/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862809
Principal investigator 1 Merck Sharp & Dohme Corporation $8,569.44 10/29/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756471
Principal investigator 1 PFIZER INC. $5,112.90 10/29/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862815
Principal investigator 1 PFIZER INC. $395.85 10/26/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742866181
Principal investigator 1 PFIZER INC. $52.00 10/26/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742866519
Principal investigator 1 PFIZER INC. $3,206.45 10/17/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862811
Principal investigator 1 PFIZER INC. $31.20 10/05/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742866179
Principal investigator 1 PFIZER INC. $237.51 10/05/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742866523
Principal investigator 1 PFIZER INC. $11,356.45 10/02/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862819
Principal investigator 1 Merck Sharp & Dohme Corporation $12,086.58 09/24/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756431
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 09/24/2020 Non-covered Recipient Entity
Filipinas Vitug
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744016919
Principal investigator 1 SANOFI PASTEUR INC. $3,500.00 09/24/2020 Non-covered Recipient Entity
Filipinas Vitug
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744016927
Principal investigator 1 Merck Sharp & Dohme Corporation $406.00 09/11/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756447
Principal investigator 1 Merck Sharp & Dohme Corporation $24.84 08/20/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756407
Principal investigator 1 Merck Sharp & Dohme Corporation $14,068.56 08/20/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756425
Principal investigator 1 Merck Sharp & Dohme Corporation $30.36 08/20/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756437
Principal investigator 1 Merck Sharp & Dohme Corporation $17.68 08/20/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756513
Principal investigator 1 Merck Sharp & Dohme Corporation $93.99 08/20/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756533
Principal investigator 1 Merck Sharp & Dohme Corporation $24.84 08/14/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756405
Principal investigator 1 Merck Sharp & Dohme Corporation $15.18 08/14/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756479
Principal investigator 1 PFIZER INC. $475.02 08/12/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742859763
Principal investigator 1 PFIZER INC. $62.40 08/12/2020 Non-covered Recipient Entity
Coast Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742859767
Principal investigator 1 Merck Sharp & Dohme Corporation $483.60 08/05/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740813785
Principal investigator 1 Merck Sharp & Dohme Corporation $7,481.10 07/23/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756529
Principal investigator 1 Merck Sharp & Dohme Corporation $24.84 07/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756403
Principal investigator 1 Merck Sharp & Dohme Corporation $30.98 07/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756441
Principal investigator 1 Merck Sharp & Dohme Corporation $35.36 07/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756445
Principal investigator 1 Merck Sharp & Dohme Corporation $45.54 07/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756473
Principal investigator 1 Merck Sharp & Dohme Corporation $203.00 07/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756537
Principal investigator 1 Merck Sharp & Dohme Corporation $187.98 07/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740813787
Principal investigator 1 Merck Sharp & Dohme Corporation $30.36 07/10/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756413
Principal investigator 1 Merck Sharp & Dohme Corporation $93.99 07/10/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756507
Principal investigator 1 Merck Sharp & Dohme Corporation $17.68 07/10/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756511
Principal investigator 1 Merck Sharp & Dohme Corporation $24.84 07/10/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756543
Principal investigator 1 Merck Sharp & Dohme Corporation $12,177.66 06/25/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756527
Principal investigator 1 Merck Sharp & Dohme Corporation $30.36 06/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756411
Principal investigator 1 Merck Sharp & Dohme Corporation $108.43 06/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756501
Principal investigator 1 Merck Sharp & Dohme Corporation $93.99 06/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756505
Principal investigator 1 Merck Sharp & Dohme Corporation $17.68 06/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756509
Principal investigator 1 Merck Sharp & Dohme Corporation $24.84 06/16/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756541
Principal investigator 1 Merck Sharp & Dohme Corporation $30.36 05/30/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756409
Principal investigator 1 Merck Sharp & Dohme Corporation $15.49 05/30/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756481
Principal investigator 1 Merck Sharp & Dohme Corporation $17.68 05/30/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756483
Principal investigator 1 Merck Sharp & Dohme Corporation $93.99 05/30/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756503
Principal investigator 1 Merck Sharp & Dohme Corporation $24.84 05/30/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756539
Principal investigator 1 Merck Sharp & Dohme Corporation $8,824.20 05/28/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756531
Principal investigator 1 Merck Sharp & Dohme Corporation $30.98 05/14/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756439
Principal investigator 1 Merck Sharp & Dohme Corporation $35.36 05/14/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756443
Principal investigator 1 Merck Sharp & Dohme Corporation $49.68 05/14/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756475
Principal investigator 1 Merck Sharp & Dohme Corporation $60.72 05/14/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756477
Principal investigator 1 Merck Sharp & Dohme Corporation $187.98 05/14/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756515
Principal investigator 1 Merck Sharp & Dohme Corporation $7,422.36 05/05/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756525
Principal investigator 1 Merck Sharp & Dohme Corporation $203.00 05/04/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756535
Principal investigator 1 Merck Sharp & Dohme Corporation $12,233.10 03/26/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756495
Principal investigator 1 Merck Sharp & Dohme Corporation $233.01 03/18/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756433
Principal investigator 1 Merck Sharp & Dohme Corporation $259.74 03/18/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756435
Principal investigator 1 Merck Sharp & Dohme Corporation $144.99 03/18/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756461
Principal investigator 1 Merck Sharp & Dohme Corporation $169.74 03/18/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756465
Principal investigator 1 Merck Sharp & Dohme Corporation $231.93 03/18/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756497
Principal investigator 1 Merck Sharp & Dohme Corporation $16,288.80 02/25/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756521
Principal investigator 1 Merck Sharp & Dohme Corporation $16.15 02/18/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756463
Principal investigator 1 Merck Sharp & Dohme Corporation $216.62 02/18/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756469
Principal investigator 1 Merck Sharp & Dohme Corporation $279.00 02/06/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756427
Principal investigator 1 Merck Sharp & Dohme Corporation $279.00 02/06/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756429
Principal investigator 1 Merck Sharp & Dohme Corporation $30,179.69 01/23/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756523
Principal investigator 1 Merck Sharp & Dohme Corporation $216.62 01/19/2020 Non-covered Recipient Entity
ALTISSIMA CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740756467